Except for the classic form of GH receptor resistance, currently known as Laron syndrome, other molecular defects leading to reduced GH sensitivity have been described, including ones in the intracellular GH signaling pathway (STAT5B, STAT3, IKBKB, IL2RG, PIK3R1), synthesis of insulin-like growth factors (IGFs) and disorders of IGF-I – insulin-like binding protein-3 – acid-labile subunit (IGFALS) complex [8,9,10]. Here, GH1 is linked to Laron syndrome.